Business Context and Reporting Period
This Form 8-K reports the results of the 2018 Annual Meeting of Stockholders held by AmerisourceBergen Corporation (now Cencora, Inc.) on March 1, 2018. The filing details the voting outcomes for eight specific items submitted to shareholders, including director elections, auditor ratification, executive compensation, and stockholder proposals.
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes Versus Prior Period
No financial material changes are reported in this document. The filing focuses solely on the discrete event of the 2018 Annual Meeting voting results.
Guidance, Outlook, and Voting Results
The filing provides the final vote counts for eight items. Management commentary and financial guidance are not included in this report.
Approved Items
- Election of Directors: All 11 nominees were elected. Notably, Ornella Barra received significant opposition (83,868,293 votes against) compared to other nominees, though she was still elected.
- Ratification of Auditor: Ernst & Young LLP was ratified as the independent registered public accounting firm for Fiscal Year 2018.
- Executive Compensation: The advisory vote to approve the compensation of Named Executive Officers was approved.
- Stock Purchase Plan: The amendment and restatement of the 2011 Employment Stock Purchase Plan was approved.
Rejected Stockholder Proposals
- Independent Chairman: A proposal to adopt a policy that the Chairman of the Board be an independent director was rejected.
- Special Meeting Threshold: A proposal regarding the ownership threshold for calling special meetings was rejected.
- Clawback Disclosure: A proposal to disclose certain incentive compensation clawbacks was rejected.
- Opioid Governance: A proposal to report on governance measures related to opioids was rejected.
Important Facts for Investor Verification
- Verify the specific reasons for the high "Against" vote count for director nominee Ornella Barra, which was significantly higher than for other nominees.
- Confirm the Board's response to the rejected stockholder proposals, particularly regarding the opioid governance disclosure and the independent chairman policy.
- Review the Definitive Proxy Statement filed on January 19, 2018, for detailed background on the proposals and director biographies.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.